scholarly journals Nonmyeloablative Conditioning Regimen Plus A2AR Agonist Oral Administration Promote Engraftment On Allogeneic Bone Marrow Transplantation Mouse Model

2013 ◽  
Vol 19 (2) ◽  
pp. S116-S117
Author(s):  
Kyu Lee Han ◽  
Stephenie V.M. Thomas ◽  
Ok Jae Koo ◽  
Sherry M. Koontz ◽  
Harry L. Malech ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Mouse Model ◽  
Oral Administration ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Conditioning Regimen ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
A2ar Agonist

Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia.

1995 ◽  
Vol 13 (12) ◽  
pp. 2973-2979 ◽  
Author(s):  
M R O'Donnell ◽  
G D Long ◽  
P M Parker ◽  
J Niland ◽  
A Nademanee ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Conditioning Regimen ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Term Survival ◽  
Long Term Survival

PURPOSE A non-radiation-containing regimen of busulfan and cyclophosphamide (BU/CY) was evaluated for toxicity, relapse, and long-term survival in patients who received allogeneic bone marrow transplantation (BMT) for myelodysplasia (MDS). PATIENTS AND METHODS Thirty-eight patients with MDS, including eight with therapy-related MDS, were prepared for BMT using BU/CY. RESULTS Fourteen patients remain in first remission 18 to 60 months posttransplant. Five patients relapsed after BMT, and four of these patients died. Eight additional patients died of acute or chronic graft-versus-host disease (GVHD), and 11 died of regimen-related toxicity, primarily systemic mycoses. Overall survival rate at 2 years was 45% (95% confidence interval [CI], 0.30 to 0.61), with a 24% probability of relapse (95% CI, 0.10 to 0.49). Regimen-related toxicity was manifested primarily as hepatic dysfunction in 72% of patients, with 16% developing overt venoocclusive disease (VOD). CONCLUSION Non-radiation-containing preparative regimens offer long-term survival in allogeneic BMT for MDS that is comparable to that of radiation-containing regimens, and are useful in patients with therapy-related MDS. Monitoring BU levels may reduce regimen-related mortality and improve survival.

scholarly journals Successful allogeneic bone marrow transplantation using immunosuppressive conditioning regimen for a patient with red blood cell transfusion-dependent pyruvate kinase deficiency anemia

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Maiko Shimomura ◽  
Takehiko Doi ◽  
Shiho Nishimura ◽  
Yusuke Imanaka ◽  
Shuhei Karakawa ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Iron Overload ◽  
Pyruvate Kinase ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Conditioning Regimen ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Pyruvate Kinase Deficiency

Pyruvate kinase deficiency (PKD) is the rare glycolytic enzyme defect causing hemolytic anemia. Treatments are mainly red cell transfusion and/or splenectomy, leading to iron overload. Allogeneic bone marrow transplantation (BMT) is alternatively curative treatment for severe PKD. The intensity of conditioning is often controversial because of higher risk of graft failure and organ damage. Here, we present a transfusion-dependent PKD patient undergoing BMT from an HLA-identical sibling using intensively immunosuppressive conditioning regimen. This report suggests that BMT using immunosuppressive conditioning regimen may be a feasible and effective treatment for patients with severe PKD with iron overload. We suggest the timing of the transplantation at an earlier age in severe PKD predicted from gene mutation is preferred before cumulative damage of transfusion.

Sign in / Sign up

Export Citation Format

Share Document